Vertex Pharmaceuticals Inc (VRTX)
VRTX - JOURNAVX Prescription Demand And Povetacicept Developments Warrant (StrongBuy)
Vertex Pharmaceuticals Non-GAAP EPS of $4.80 beats by $0.22, revenue of $3.08B beats by $20M
(Earnings Call Insights) Vertex signals 8–9% 2025 revenue growth as renal pipeline accelerates and ALYFTREK, JOURNAVX launches drive diversification
Vertex Pharmaceuticals_Trikafta And Alyftrek Cement Market Leadership (Buy)
Vertex Pharmaceuticals Buying The CF Fortress For The Journavx Optionality (Buy)
